Cresco Labs (CL) Resumen de Acciones
Cresco Labs Inc. cultiva, fabrica y vende al por menor productos de cannabis medicinal en Estados Unidos. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 5/6 |
| Crecimiento futuro | 0/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 3/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
CL Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Cresco Labs Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | CA$1.38 |
| Máximo en las últimas 52 semanas | CA$3.12 |
| Mínimo de 52 semanas | CA$0.60 |
| Beta | 1.65 |
| Cambio en 1 mes | 27.78% |
| Variación en 3 meses | -2.13% |
| Cambio de 1 año | 2.22% |
| Variación en 3 años | -32.02% |
| Variación en 5 años | -91.51% |
| Variación desde la OPV | -78.93% |
Noticias y actualizaciones recientes
CL: Discount-Adjusted Outlook Will Support Future Upside From Speculative Buy Rating
Analysts have trimmed their CA$ price target on Cresco Labs from CA$2.50 to CA$2.25, reflecting updated expectations for the discount rate, profit margin and future P/E assumptions. Analyst Commentary The revised CA$2.25 price target signals that analysts are updating their view of Cresco Labs as they refresh discount rate, margin and P/E assumptions, rather than completely changing their stance on the business.CL: Revised Outlook Will Support Future Upside From Speculative Buy Rating
Analysts have reduced their price target on Cresco Labs to CA$2.25 from CA$2.50, citing updated assumptions regarding fair value, discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Analysts have adjusted their view on Cresco Labs by trimming the price target to CA$2.25 from CA$2.50 while maintaining a Speculative Buy stance, which reflects both perceived upside potential and meaningful execution risk.
CL: Lower P/E Assumptions Will Support A More Upside-Skewed Outlook
Analysts now see Cresco Labs' fair value as aligning with a trimmed CA$2.25 price target, down from CA$2.50. This reflects updated views on growth, margins and a lower future P/E assumption.Recent updates
CL: Discount-Adjusted Outlook Will Support Future Upside From Speculative Buy Rating
Analysts have trimmed their CA$ price target on Cresco Labs from CA$2.50 to CA$2.25, reflecting updated expectations for the discount rate, profit margin and future P/E assumptions. Analyst Commentary The revised CA$2.25 price target signals that analysts are updating their view of Cresco Labs as they refresh discount rate, margin and P/E assumptions, rather than completely changing their stance on the business.CL: Revised Outlook Will Support Future Upside From Speculative Buy Rating
Analysts have reduced their price target on Cresco Labs to CA$2.25 from CA$2.50, citing updated assumptions regarding fair value, discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Analysts have adjusted their view on Cresco Labs by trimming the price target to CA$2.25 from CA$2.50 while maintaining a Speculative Buy stance, which reflects both perceived upside potential and meaningful execution risk.CL: Lower P/E Assumptions Will Support A More Upside-Skewed Outlook
Analysts now see Cresco Labs' fair value as aligning with a trimmed CA$2.25 price target, down from CA$2.50. This reflects updated views on growth, margins and a lower future P/E assumption.CL: Higher Future P/E Assumptions Will Shape A More Upside-Skewed Outlook
Analysts have lowered their price target on Cresco Labs to CA$2.25 from CA$2.50, reflecting updated views on revenue growth, profit margins, and a much higher assumed future P/E multiple. Analyst Commentary Bearish analysts are signaling a more cautious stance on Cresco Labs by trimming their price target to CA$2.25 from CA$2.50, even while still seeing speculative upside potential.CL: Expanded Retail Footprint And Flexible Equity Program Will Support A More Optimistic Outlook
Analysts have revised their price target on Cresco Labs to CA$16.91 from CA$18.36, reflecting updated views on discount rates, revenue growth, profit margins, and future P/E assumptions. What's in the News Cresco Labs filed a follow on equity offering for up to CA$140 million of Subordinate Voting Shares through an at the market program, giving the company flexibility to raise capital over time (Key Developments).Cresco Labs Inc. (CSE:CL) Shares Slammed 29% But Getting In Cheap Might Be Difficult Regardless
Feb 12
CL: Expanded Retail And EU Entry Will Support A More Optimistic Outlook
Analysts have lifted their price target on Cresco Labs to US$1.94 from US$1.51, citing revised assumptions around revenue growth, profit margins, discount rate, and a lower future P/E multiple as key drivers of the change. What's in the News Cresco Labs filed a follow on equity offering of up to C$140 million in subordinate voting shares through an at the market program, adding flexibility to raise capital as needed (Key Developments).CL: New German Entry Will Support Future Upside
Analysts have nudged their price target for Cresco Labs higher, now implying fair value of about $2.40 per share versus roughly $2.36 previously. The change reflects updated views on revenue growth, profit margins and future P/E assumptions.CL: German Entry And Higher Margins Will Support Future Upside
Analysts have raised their price target for Cresco Labs from US$2.30 to about US$2.36, reflecting updated views on the company’s profit margin outlook and a lower assumed future P/E multiple. What's in the News Cresco Labs launched Cresco branded flower in Germany, marking its first commercial entry into the European Union and extending its growth plans beyond the U.S. cannabis market (Key Developments).CL: Expanded Retail And European Entry Will Support Stronger Profitability
Analysts have modestly raised their price target on Cresco Labs to reflect an updated fair value estimate of approximately 2.30 dollars, up from about 2.16 dollars previously, citing expectations for stronger revenue growth, improved profit margins, a slightly lower discount rate, and a more reasonable future earnings multiple. What's in the News Entered the European Union with the launch of Cresco branded flower in Germany, using the market as a testbed for broader international expansion beyond U.S. cannabis (Key Developments).Cresco Labs Inc. (CSE:CL) Not Doing Enough For Some Investors As Its Shares Slump 37%
Nov 26Here's Why Cresco Labs (CSE:CL) Is Weighed Down By Its Debt Load
Nov 08Optimistic Investors Push Cresco Labs Inc. (CSE:CL) Shares Up 35% But Growth Is Lacking
Oct 12Is Cresco Labs Inc. (CSE:CL) Trading At A 49% Discount?
Sep 06Optimistic Investors Push Cresco Labs Inc. (CSE:CL) Shares Up 27% But Growth Is Lacking
Jul 31Cresco Labs (CSE:CL) Takes On Some Risk With Its Use Of Debt
Jul 23Cresco Labs Inc.'s (CSE:CL) 30% Share Price Plunge Could Signal Some Risk
Jun 15Cresco Labs Inc.'s (CSE:CL) Shares Climb 31% But Its Business Is Yet to Catch Up
May 01
Expanding Production In Illinois, Pennsylvania And Kentucky Will Meet Demand
Expansion in Illinois and Pennsylvania and entry into Kentucky's market aim to boost revenue growth and market share.Some Confidence Is Lacking In Cresco Labs Inc. (CSE:CL) As Shares Slide 27%
Mar 07Is Cresco Labs (CSE:CL) A Risky Investment?
Jan 31Cresco Labs Inc. (CSE:CL) May Have Run Too Fast Too Soon With Recent 28% Price Plummet
Dec 14Getting In Cheap On Cresco Labs Inc. (CSE:CL) Is Unlikely
Oct 24Cresco Labs Inc. (CSE:CL) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates
Aug 11Are Investors Undervaluing Cresco Labs Inc. (CSE:CL) By 34%?
Jul 17Here's Why Cresco Labs (CSE:CL) Has A Meaningful Debt Burden
Jun 19Cresco Labs Inc.'s (CSE:CL) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Jun 19Cresco Labs Inc. (CSE:CL) Released Earnings Last Week And Analysts Lifted Their Price Target To CA$5.41
Mar 16Investors Don't See Light At End Of Cresco Labs Inc.'s (CSE:CL) Tunnel And Push Stock Down 32%
Mar 03Cresco Labs (CSE:CL) Seems To Be Using A Lot Of Debt
Jan 26Risks To Shareholder Returns Are Elevated At These Prices For Cresco Labs Inc. (CSE:CL)
Jan 04Rentabilidad de los accionistas
| CL | CA Pharmaceuticals | Mercado CA | |
|---|---|---|---|
| 7D | -15.9% | -5.7% | -1.7% |
| 1Y | 2.2% | 38.9% | 33.8% |
Rentabilidad vs. Industria: Los resultados de CL fueron inferiores a los de la industria Canadian Pharmaceuticals, que obtuvo un rendimiento del 38.9% el año pasado.
Rentabilidad vs. Mercado: CL obtuvo unos resultados inferiores a los del mercado Canadian, que fueron del 33.8% el año pasado.
Volatilidad de los precios
| CL volatility | |
|---|---|
| CL Average Weekly Movement | 17.4% |
| Pharmaceuticals Industry Average Movement | 11.5% |
| Market Average Movement | 10.8% |
| 10% most volatile stocks in CA Market | 18.2% |
| 10% least volatile stocks in CA Market | 3.9% |
Precio estable de las acciones: El precio de las acciones de CL ha sido volátil durante los últimos 3 meses en comparación con el mercado Canadian.
Volatilidad a lo largo del tiempo: La volatilidad semanal de CL(17%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de Canadian.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| n/a | 2,900 | Charlie Bachtell | www.crescolabs.com |
Cresco Labs Inc. cultiva, fabrica y vende al por menor productos de cannabis medicinal en Estados Unidos. Ofrece cannabis en flores, vaporizadores, resinas vivas, bolígrafos desechables y extractos bajo la marca Cresco; carros de vaporización, vaporizadores, flores, palomitas de maíz, batidos, pre-rolls, shorties y concentrados bajo la marca High Supply; vaporizadores y gominolas bajo la marca Good News; vaporizadores y comestibles bajo la marca Wonder Wellness Co.; y tinturas, cápsulas, bálsamos y aceites sublinguales bajo la marca Remedi. La empresa ofrece flores de cannabis bajo la marca FloraCal; y aceites de cannabis y variedad de bocados disponibles en múltiples niveles de potencia bajo la marca Mindy's Edibles, así como licencias de la marca Kiva.
Resumen de fundamentos de Cresco Labs Inc.
| Estadísticas fundamentales de CL | |
|---|---|
| Capitalización bursátil | CA$673.60m |
| Beneficios(TTM) | -CA$185.27m |
| Ingresos (TTM) | CA$897.37m |
¿Está CL sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de CL | |
|---|---|
| Ingresos | US$655.85m |
| Coste de los ingresos | US$331.28m |
| Beneficio bruto | US$324.57m |
| Otros gastos | US$459.98m |
| Beneficios | -US$135.41m |
Últimos beneficios comunicados
Dec 31, 2025
Próxima fecha de beneficios
May 08, 2026
| Beneficios por acción (BPA) | -0.37 |
| Margen bruto | 49.49% |
| Margen de beneficio neto | -20.65% |
| Ratio deuda/patrimonio | 132.1% |
¿Cómo se ha desempeñado CL a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/04/29 15:22 |
| Precio de las acciones al final del día | 2026/04/29 00:00 |
| Beneficios | 2025/12/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Cresco Labs Inc. está cubierta por 13 analistas. 7 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Aaron Grey | Alliance Global Partners |
| Frederico Yokota Choucair Gomes | ATB Cormark |
| Russell Stanley | Beacon Securities Limited |